INTRODUCTION: Erlotinib has prolonged survival in unselected patients with advanced non-small cell lung cancer, whereas sunitinib has yielded promising rates of disease control in previously treated patients. We conducted a dose escalation study of this combination to determine the maximum tolerated dose of sunitinib in combination with a fixed dose of erlotinib and to evaluate the toxicities of this combination. METHODS: Patients with advanced nonsquamous non-small cell lung cancer were treated at two dose levels: sunitinib at either 25 mg or 37.5 mg, with erlotinib 150 mg. Both drugs were given once daily, continuously. RESULTS: Eleven patients enrolled from November 2007 to October 2009. No dose-limiting toxicities occurred. Grade 3/4 adverse events at least possibly related to treatment were seen in seven patients (64%). Six patients (54%) required dose modifications, and three (27%) discontinued study treatment due to toxicity. Rates of grade 3 diarrhea and mucositis exceeded those seen with single-agent erlotinib or sunitinib. One patient (9%) attained a partial response lasting 16.3 months. CONCLUSIONS: Although no dose-limiting toxicities occurred, it is difficult to recommend erlotinib 150 mg and sunitinib 37.5 mg daily as the phase II dose for this combination due to the high rate of adverse events. Because of the overlapping toxicity profile of each agent, this combination was poorly tolerated in our population.
INTRODUCTION:Erlotinib has prolonged survival in unselected patients with advanced non-small cell lung cancer, whereas sunitinib has yielded promising rates of disease control in previously treated patients. We conducted a dose escalation study of this combination to determine the maximum tolerated dose of sunitinib in combination with a fixed dose of erlotinib and to evaluate the toxicities of this combination. METHODS:Patients with advanced nonsquamous non-small cell lung cancer were treated at two dose levels: sunitinib at either 25 mg or 37.5 mg, with erlotinib 150 mg. Both drugs were given once daily, continuously. RESULTS: Eleven patients enrolled from November 2007 to October 2009. No dose-limiting toxicities occurred. Grade 3/4 adverse events at least possibly related to treatment were seen in seven patients (64%). Six patients (54%) required dose modifications, and three (27%) discontinued study treatment due to toxicity. Rates of grade 3 diarrhea and mucositis exceeded those seen with single-agent erlotinib or sunitinib. One patient (9%) attained a partial response lasting 16.3 months. CONCLUSIONS: Although no dose-limiting toxicities occurred, it is difficult to recommend erlotinib 150 mg and sunitinib 37.5 mg daily as the phase II dose for this combination due to the high rate of adverse events. Because of the overlapping toxicity profile of each agent, this combination was poorly tolerated in our population.
Authors: Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245
Authors: Joline S W Lind; Anne-Marie C Dingemans; Harry J M Groen; Frederik B Thunnissen; Otto Bekers; Daniëlle A M Heideman; Richard J Honeywell; Elisa Giovannetti; Godefridus J Peters; Pieter E Postmus; Robert Jan van Suylen; Egbert F Smit Journal: Clin Cancer Res Date: 2010-04-15 Impact factor: 12.531
Authors: Miguel Quintela-Fandino; Christophe Le Tourneau; Ignacio Duran; Eric X Chen; Lisa Wang; Ming Tsao; Bizhan Bandarchi-Chamkhaleh; Nhu-Ann Pham; Trevor Do; Martha MacLean; Rakesh Nayyar; Michael W Tusche; Ur Metser; John J Wright; Tak W Mak; Lillian L Siu Journal: Mol Cancer Ther Date: 2010-03-02 Impact factor: 6.261
Authors: Mark A Socinski; Silvia Novello; Julie R Brahmer; Rafael Rosell; Jose M Sanchez; Chandra P Belani; Ramaswamy Govindan; James N Atkins; Heidi H Gillenwater; Cinta Pallares; Lesley Tye; Paulina Selaru; Richard C Chao; Giorgio V Scagliotti Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: S Novello; G V Scagliotti; R Rosell; M A Socinski; J Brahmer; J Atkins; C Pallares; R Burgess; L Tye; P Selaru; E Wang; R Chao; R Govindan Journal: Br J Cancer Date: 2009-10-13 Impact factor: 7.640
Authors: George N Naumov; Monique B Nilsson; Tina Cascone; Alexandra Briggs; Oddbjorn Straume; Lars A Akslen; Eugene Lifshits; Lauren Averett Byers; Li Xu; Hua-Kang Wu; Pasi Jänne; Susumu Kobayashi; Balazs Halmos; Daniel Tenen; Xi M Tang; Jeffrey Engelman; Beow Yeap; Judah Folkman; Bruce E Johnson; John V Heymach Journal: Clin Cancer Res Date: 2009-05-15 Impact factor: 12.531
Authors: Fortunato Ciardiello; Roberto Bianco; Roberta Caputo; Rosa Caputo; Vincenzo Damiano; Teresa Troiani; Davide Melisi; Ferdinando De Vita; Sabino De Placido; A Raffaele Bianco; Giampaolo Tortora Journal: Clin Cancer Res Date: 2004-01-15 Impact factor: 12.531